Solution for Water scarcity Problem in Construction

These paper is discusses about implementation of sewage water in construction. As per ISI, water demand for residential building is more than commercial building. As we know in residential building water is uses for various things such as for kitchen, bath room, drinking, washing clothes and utensils, toilet flushing etc. Sewage water is the water which collected from kitchen sink, bathroom water which are used for these create a waste. The paper discuses about how we can use that waste water in construction. If instead of creating waste, we are doing recycling of that sewage water and used in construction. If we do recycling of waste water then automatically the demand of water required for construction is automatically decreases. The paper discuses about sewage water treatment with the use of Biosanitizer Ecochips ad its implementation in construction. Also the paper discuses about the experimental research on implementation of sewage water in construction.The paper are discusses the study of effect of raw sewage water and treated sewage water on concrete strength. In ecological approach, ecochips are used for recycling of waste water. Use of treated waste water gives strength to concrete.The paper also discusses the economical point of view for using Ecochips for raw sewage water treatment. These paper has gives guidelines to carry out study of implementation of sewage water in construction field and useful to reduces the water problem in construction field also helps to reduce the total water demand loa

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.

PURPOSE: Chimeric antigen receptor modified T cells (CAR-T) have demonstrated encouraging results in early-phase clinical trials. Successful adaptation of CAR-T technology for CEA-expressing adenocarcinoma liver metastases (LM), a major cause of death in patients with gastrointestinal cancers, has yet to be achieved. We sought to test intrahepatic delivery of anti-CEA CAR-T through percutaneous hepatic artery infusions (HAI). EXPERIMENTAL DESIGN: We conducted a phase I trial to test HAI of CAR-T in patients with CEA+ LM. Six patients completed the protocol, and 3 received anti-CEA CAR-T HAIs alone in dose-escalation fashion (10(8), 10(9), and 10(10) cells). We treated an additional 3 patients with the maximum planned CAR-T HAI dose (10(10) cells X 3) along with systemic IL2 support. RESULTS: Four patients had more than 10 LM and patients received a mean of 2.5 lines of conventional systemic therapy prior to enrollment. No patient suffered a grade 3 or 4 adverse event related to the CAR-T HAIs. One patient remains alive with stable disease at 23 months following CAR-T HAI and 5 patients died of progressive disease. Among the patients in the cohort that received systemic IL2 support, CEA levels decreased 37% (range 19–48%) from baseline. Biopsies demonstrated an increase in LM necrosis or fibrosis in 4 of 6 patients. Elevated serum IFNγ levels correlated with IL2 administration and CEA decreases. CONCLUSIONS: We have demonstrated the safety of anti-CEA CAR-T HAIs with encouraging signals of clinical activity in a heavily pre-treated population with large tumor burdens. Further clinical testing of CAR-T HAIs for LM is warranted